Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Dicerna Pharmaceuticals stock

Learn how to easily invest in Dicerna Pharmaceuticals stock.

Dicerna Pharmaceuticals is a biotechnology business based in the US. Dicerna Pharmaceuticals shares (DRNA) are listed on the NASDAQ and all prices are listed in US Dollars. Dicerna Pharmaceuticals employs 302 staff and has a trailing 12-month revenue of around $192.9 million.

How to buy Dicerna Pharmaceuticals stock

  1. Open a stock trading account. Use our comparison table or choose from our Top Picks.
  2. Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
  3. Search for the stock by name or ticker symbol – DRNA. It's that simple.

Best for low fees

Finder Award

SoFi Invest

  • Trade stocks for $0 and no annual fee
  • Start trading with a $0 minimum deposit
  • Get up to $1,000 when you fund a new account within 30 days

Promoted for easy user experience


  • Commission-free trading
  • Commission-free crypto
  • No minimum account balance



  • $0 commissions on stocks and ETFs
  • $0 closing commissions on stock and ETF options
  • Get $200 in US stocks when you open and fund an account with min. $2,000 for 3+ mos.

Dicerna Pharmaceuticals stock price (NASDAQ: DRNA)

Use our graph to track the performance of DRNA stocks over time.

Dicerna Pharmaceuticals shares at a glance

Information last updated 2022-02-20.
Latest market close$38.22
52-week range$0.00 - $0.00
50-day moving average $31.45
200-day moving average $28.97
Wall St. target price$38.25
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.63

Buy Dicerna Pharmaceuticals stocks from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 5 of 5
Name Product Available asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, Options, ETFs, Cryptocurrency
Get up to $1,000
when you fund a new account within 30 days.
Winner of Finder’s Best Low-Cost Broker award.
Stocks, Options, ETFs, Cryptocurrency
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 4% interest on uninvested cash in your account with Robinhood Gold.
Stocks, Options, ETFs, Cryptocurrency
Get $200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Highly commended for Best Derivatives Trading Platform award.
Stocks, ETFs, Cryptocurrency, Alternatives
Get up to $300 in either stocks or crypto
when you use code FINDERUS to sign up and fund a new account.
Trade stocks and ETFs commission-free, plus gain access to alternative investments like art, NFTs and more.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency, Futures, Forex
Winner of Finder’s Best Overall Stock Broker award.

Compare up to 4 providers

*Signup bonus information updated weekly.

Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.

Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.

Is it a good time to buy Dicerna Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Dicerna Pharmaceuticals price performance over time

Historical closes compared with the close of $38.22 from 2021-12-29

1 week (2023-01-16) N/A
1 month (2022-12-23) N/A
3 months (2022-10-23) N/A
6 months (2022-07-23) N/A
1 year (2022-01-23) N/A
2 years (2021-01-27) 55.24%
3 years (2020-01-27) 101.80%
5 years (2018-01-26) 278.79%

Dicerna Pharmaceuticals financials

Revenue TTM $192.9 million
Gross profit TTM $-41,077,000
Return on assets TTM -10.43%
Return on equity TTM -95.22%
Profit margin -64.53%
Book value $1.38
Market capitalisation $3 billion

TTM: trailing 12 months

Dicerna Pharmaceuticals share dividends

We're not expecting Dicerna Pharmaceuticals to pay a dividend over the next 12 months.

Dicerna Pharmaceuticals share price volatility

Over the last 12 months, Dicerna Pharmaceuticals's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".

DRNA.US volatility(beta: 0.79)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Dicerna Pharmaceuticals's is 0.786. This would suggest that Dicerna Pharmaceuticals's shares are less volatile than average (for this exchange).

Dicerna Pharmaceuticals overview

Dicerna Pharmaceuticals, Inc. , a biopharmaceutical company, focuses on the discovery, development, and commercializing of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare, cardiometabolic, viral, and chronic liver diseases; complement-mediated diseases; and neurodegenerative diseases and pain. Its principal development programs include nedosiran for the treatment of primary hyperoxaluria; RG6346 for the treatment of chronic hepatitis B virus infection; belcesiran for the treatment of deficiency-associated liver disease; and DCR-AUD for the treatment of alcohol use disorder. Dicerna Pharmaceuticals, Inc. has strategic collaborations with Novo Nordisk A/S, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.

Frequently asked questions

What percentage of Dicerna Pharmaceuticals is owned by insiders or institutions?
Currently 7.434% of Dicerna Pharmaceuticals shares are held by insiders and 88.539% by institutions.
How many people work for Dicerna Pharmaceuticals?
Latest data suggests 302 work at Dicerna Pharmaceuticals.
When does the fiscal year end for Dicerna Pharmaceuticals?
Dicerna Pharmaceuticals's fiscal year ends in December.
Where is Dicerna Pharmaceuticals based?
Dicerna Pharmaceuticals's address is: 75 Hayden Avenue, Lexington, MA, United States, 02421
What is Dicerna Pharmaceuticals's ISIN number?
Dicerna Pharmaceuticals's international securities identification number is: US2530311081
What is Dicerna Pharmaceuticals's CUSIP number?
Dicerna Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 253031108

More guides on Finder

Ask an Expert provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site